A paradigm shift of the biopharmaceutical industry has been seen in the movement towards cell and gene therapy production, where there is a need to adopt sophisticated and state-of-the-art single-use bioreactor systems with complex automation architectures. This academic paper provides a detailed outline of hierarchical control measures to be applied in the single-use bioreactor systems, in particular, that have to face the challenges of compliant film materials, restrictions of sensors, and dynamic working conditions. The article explores fundamental process control elements, including dissolved oxygen regulation, pH management, temperature stability, and agitation control, while examining the integration of continuous perfusion systems utilizing alternating tangential flow technology and discrete media exchange protocols coordinated with centrifugation equipment. Emphasis is placed on the systematic development of recipe-layer architectures that enable process scientists to configure complex operational sequences through parameterized phases rather than direct control code modification, thereby maintaining validation status across diverse therapeutic products and manufacturing scales. The control strategies discussed enable process intensification, achieving substantially higher cell densities and volumetric productivities while maintaining product quality attributes essential for viral vector production, engineered cell therapies, and stem-cell-derived therapeutics. The framework addresses critical regulatory considerations, including data integrity, electronic batch record integration, and risk mitigation strategies for potential failure modes. As the field advances toward increasingly complex cellular products and automated manufacturing paradigms, the automation architectures presented serve as foundational elements supporting the transition from traditional bioprocessing toward intelligent, adaptive manufacturing systems capable of responding to biological variability and process dynamics in real-time.